 Celecoxib
"Celecoxib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.
| Descriptor ID |
D000068579
|
| MeSH Number(s) |
D02.065.884.247 D02.886.590.700.247 D03.383.129.539.160
|
| Concept/Terms |
Celecoxib- Celecoxib
- 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
SC 58635- SC 58635
- 58635, SC
- SC-58635
- SC58635
|
Below are MeSH descriptors whose meaning is more general than "Celecoxib".
Below are MeSH descriptors whose meaning is more specific than "Celecoxib".
This graph shows the total number of publications written about "Celecoxib" by people in this website by year, and whether "Celecoxib" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 4 | 4 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 3 | 3 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 4 | 4 | | 2014 | 0 | 2 | 2 | | 2016 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Celecoxib" by people in Profiles.
-
Viscusi ER, de Leon-Casasola O, Cebrecos J, Jacobs A, Morte A, Ortiz E, Sust M, Vaqu? A, Gottlieb I, Daniels S, Gimbel JS, Muse D, Winkle P, Kuss ME, Videla S, Gasc?n N, Plata-Salam?n C. Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: A phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial. Pain Pract. 2023 01; 23(1):8-22.
-
Riva B, De Dominici M, Gnemmi I, Mariani SA, Minassi A, Minieri V, Salomoni P, Canonico PL, Genazzani AA, Calabretta B, Condorelli F. Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of ?-catenin and mTORC1/2. Oncotarget. 2016 Dec 06; 7(49):81555-81570.
-
Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, Bhattacharyya A, Hsu CH, Chow SH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez EM, Alberts DS, Lance P. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. J Natl Cancer Inst. 2016 12; 108(12).
-
Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L, Keely P. COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res. 2016 Mar 22; 18(1):35.
-
Lyons TR, Borges VF, Betts CB, Guo Q, Kapoor P, Martinson HA, Jindal S, Schedin P. Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. J Clin Invest. 2014 Sep; 124(9):3901-12.
-
Kim SJ, Toma H, Shah R, Kompella UB, Vooturi SK, Sheng J. The safety, pharmacokinetics, and efficacy of intraocular celecoxib. Invest Ophthalmol Vis Sci. 2014 Mar 10; 55(3):1409-18.
-
Altman R, Daniels S, Young CL. Indomethacin submicron particle capsules provide effective pain relief in patients with acute pain: a phase 3 study. Phys Sportsmed. 2013 Nov; 41(4):7-15.
-
Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, M?ller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, Beitler JJ, Nannapaneni S, Shin HJ, Grandis JR, Khuri FR, Chen ZG, Shin DM. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila). 2014 Mar; 7(3):283-91.
-
Dhanda DS, Tyagi P, Mirvish SS, Kompella UB. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release. 2013 Jun 28; 168(3):239-50.
-
Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, M?ller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, Chen ZG. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res. 2013 Mar 01; 19(5):1244-56.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|